We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

39 hedge funds and large institutions have $8.1M invested in vTv Therapeutics in 2020 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 7

200% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 4

82% more capital invested

Capital invested by funds: $4.44M → $8.1M (+$3.66M)

56% more funds holding

Funds holding: 25 → 39 (+14)

0.06% more ownership

Funds ownership: 0.14% → 0.2% (+0.06%)

Holders
39
Holders Change
+14
Holders Change %
+56%
% of All Funds
0.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
12
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$657K
2
Two Sigma Investments
Two Sigma Investments
New York
+$475K
3
State Street
State Street
Massachusetts
+$435K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$401K
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$311K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$401K
2
Millennium Management
Millennium Management
New York
-$93K
3
SIM
Spark Investment Management
New York
-$46K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$31K
5
JG
Jefferies Group
New York
-$27K
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
$12K +$8.89K +90 +220%
Wells Fargo
27
Wells Fargo
California
$12K +$12.2K +124 +1,033%
Deutsche Bank
28
Deutsche Bank
Germany
$10K -$9.38K -95 -46%
UBS Group
29
UBS Group
Switzerland
$9K +$8.2K +83 +332%
Morgan Stanley
30
Morgan Stanley
New York
$8K +$7.41K +75 +577%
Osaic Holdings
31
Osaic Holdings
Arizona
$5K – – –
Legal & General Group
32
Legal & General Group
United Kingdom
$4K +$4.74K +48 New
Citigroup
33
Citigroup
New York
$3K +$2.96K +30 New
PA
34
Parallel Advisors
California
$3K +$3.75K +38 New
Bank of Montreal
35
Bank of Montreal
Ontario, Canada
$2K +$1.88K +19 New
SSB
36
Sandy Spring Bank
Maryland
$2K +$1.88K +19 New
AIP
37
Ameritas Investment Partners
Nebraska
$2K +$2.07K +21 New
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
$1K -$395 -4 -33%
BNP Paribas Financial Markets
39
BNP Paribas Financial Markets
France
$826 +$889 +9 New
Millennium Management
40
Millennium Management
New York
– -$93K -1,221 Closed
SIM
41
Spark Investment Management
New York
– -$46K -605 Closed
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
– -$31K -407 Closed
JG
43
Jefferies Group
New York
– -$27K -350 Closed
PNC Financial Services Group
44
PNC Financial Services Group
Pennsylvania
– -$10K -125 Closed
Victory Capital Management
45
Victory Capital Management
Texas
– -$6K -68 Closed
1
2

VTVT Hedge Fund Activity: Q2 2020 in Review

39 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q2 2020, worth a combined $8.1M — up 82% from $4.44M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new VTVT positions and 7 closed out — a net gain of 14 holders — while 12 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $657K. The largest seller was Renaissance Technologies, cutting an estimated $401K.

  • 39 institutional investors held vTv Therapeutics (VTVT) as of Q2 2020, up from 25 in Q1 2020.
  • Funds reported $8.1M of vTv Therapeutics stock for Q2 2020, up 82% quarter-over-quarter.
  • 21 funds opened new vTv Therapeutics positions in Q2 2020 and 7 closed out, a net change of +14 holders.
  • The largest vTv Therapeutics buyer in Q2 2020 was BlackRock, an estimated $657K added.
  • The largest vTv Therapeutics seller in Q2 2020 was Renaissance Technologies, an estimated $401K sold.

Based on aggregated 13F filings for Q2 2020.